IONS IONIS PHARMACEUTICALS INC Product Launches 8-K Filing 2024 - Product Launch Ionis Pharmaceuticals announced positive results for the Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema (HAE).Get access to all SEC 8-K filings of the IONIS PHARMACEUTICALS INC